CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
CRISPR Therapeutics AG
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$50.04+0.79 (+1.60%)
Close on Oct 19, 2026
- Market cap
- $4.83B
- P/E (TTM)
- –
- Dividend yield
- –
CRISPR Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | CRISPR Therapeutics | Industry median |
|---|---|---|
| Market Cap | $4.84B | $166.30M |
| Enterprise Value | $2.47B | $88.19M |
| PS Ratio | 361.30 | 3.65 |
| PB Ratio | 2.77 | 2.03 |
| P/TBV Ratio | 2.77 | 2.29 |
Enterprise value
| Measure | CRISPR Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 184.75 | 2.51 |
Income (trailing twelve months)
| Measure | CRISPR Therapeutics | Industry median |
|---|---|---|
| Revenue | $13.39M | $58.34M |
| Operating Income | -$534.34M | -$21.40M |
| Pretax Income | -$448.11M | -$14.34M |
| Net Income | -$451.14M | -$22.46M |
| EBITDA | -$515.65M | -$16.91M |
| EPS (Diluted) | -$4.76 | -$0.83 |
Margins
| Measure | CRISPR Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -3990.0% | -44.0% |
| Pretax Margin | -3346.1% | -13.3% |
| Profit Margin | -3368.7% | -40.2% |
| EBITDA Margin | -3850.4% | -30.2% |
| FCF Margin | -2772.7% | -9.27% |
Returns
| Measure | CRISPR Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -26.1% | -53.2% |
| Return on Assets (ROA) | -19.3% | -40.9% |
| Return on Capital Employed (ROCE) | -21.2% | -38.1% |
Growth
| Measure | CRISPR Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -64.8% | 5.96% |
| Revenue Growth (3Y CAGR) | 43.1% | 2.25% |
| Revenue Growth (5Y CAGR) | 37.3% | 6.48% |
Balance sheet
| Measure | CRISPR Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $2.36B | $61.43M |
| Net Cash (Debt) | $2.36B | $15.35M |
| Net Cash Per Share | $24.45 | $0.66 |
| Equity (Book Value) | $1.75B | $49.09M |
| Book Value Per Share | $18.06 | $1.37 |
| Tangible Book Value | $1.75B | $23.52M |
| Working Capital | $2.24B | $76.81M |
Financial position
| Measure | CRISPR Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 17.85 | 3.34 |
| Quick Ratio | 17.79 | 2.44 |
Cash flow (trailing twelve months)
| Measure | CRISPR Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$369.58M | -$12.35M |
| Capital Expenditures | -$1.74M | -$1.08M |
| Free Cash Flow | -$371.33M | -$20.22M |
| FCF Per Share | -$3.84 | -$0.42 |
Efficiency
| Measure | CRISPR Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.01 | 0.39 |
| Revenue Per Employee | $34.08K | $404.87K |
| Profits Per Employee | -$1.15M | -$703.34K |
| Employee Count | 393 | 74 |
Dividends and yields
| Measure | CRISPR Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -9.32% | -23.3% |
| FCF Yield | -7.67% | -8.72% |
| Buyback Yield | -8.04% | -0.59% |
| Shareholder Yield | -8.04% | 0.00% |
Shares
| Measure | CRISPR Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 96,692,700 | 58,127,000 |
| Shares Change (YoY) | 10.3% | 10.9% |
| Shares Change (QoQ) | 0.29% | 0.54% |
| Float | 94,121,200 | 49,136,700 |
| Shares Held by Insiders | 2.66% | 11.6% |
Taxes
| Measure | CRISPR Therapeutics | Industry median |
|---|---|---|
| Income Tax | $3.03M | $79.87K |
Scores
| Measure | CRISPR Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 2.42 | -0.22 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from CRISPR Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.